Navigation Links
ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
Date:4/23/2008

TUCSON, Ariz., April 23 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it has entered into an agreement with Abbott Laboratories pursuant to which it has satisfied its obligations under its $15 million non-recourse promissory note with Abbott issued in connection with its acquisition of urokinase. As a result, full title to the urokinase assets, including the remaining inventory of finished product, all regulatory and clinical documentation, validated cell lines, and intellectual property rights, now resides unencumbered with ImaRx.

Urokinase is a thrombolytic drug, formerly marketed under the brand name Abbokinase(R) and recently re-branded as Kinlytic(TM). Urokinase is FDA approved and marketed for the treatment of acute massive pulmonary embolism, or blood clots in the lungs.

As of March 31, 2008, the remaining balance due under the note net of funds that were held in escrow totaled approximately $10.8 million. Pursuant to the terms of the agreement, all of ImaRx's obligations under the $15 million non-recourse promissory note were fully satisfied in exchange for the payment of $5,177,609 in cash to Abbott and the satisfaction of certain payment obligations relating to the storage of certain cell banks and recombinant samples at a contract research organization.

Bradford A. Zakes, President and CEO of ImaRx Therapeutics, stated, "We are pleased to have reached agreement with Abbott Laboratories on the satisfaction of this debt obligation. This now ensures that we have complete ownership of the asset, which will enable us to continue to commercialize this product and to provide patients and their doctors access to this important therapeutic."

About ImaRx Therapeutics '/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
2. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. ImaRx to Report Corporate Updates and 4Q07 Financial Results
5. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
6. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
7. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
8. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
9. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
10. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
11. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... SEATTLE , April 1, 2015  Adaptive ... The Lancet Oncology showing ... the company,s next-generation sequencing-based minimal residual disease (MRD) ... clonoSEQ™ MRD test) accurately identifies patients with diffuse ... of relapse after initial treatment, usually several months ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 ... (AFM) was selected to receive the prestigious “Best ... Economy Magazine.    Park NX10 is the premium research-grade True ... Z scanner linearity, closed-loop detector noise, and minimized ... SmartSca n, which allows images with a ...
(Date:4/1/2015)... April 1, 2015 /PRNewswire/ - Portage Biotech Inc. ... is pleased to announce that Biohaven Pharmaceutical Holding ... has entered into an agreement with inVentiv Health ... trial with their lead compound (BHV-0223). ... development of clinical stage neuroscience compounds targeting the ...
(Date:4/1/2015)... 1, 2015  Among 1,050 U.S. consumers, the majority ... (68 percent) and only 36 percent reported being screened ... to findings from a survey released today ... and developer of solutions that aid in the early ... survey polled 1,050 U.S. consumers on their knowledge of ...
Breaking Biology Technology:Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4
... Reportlinker.com announces that a new market ... Animal Biotechnology - Technologies, ... http://www.reportlinker.com/p0203534/Animal-Biotechnology---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology Summary ... animal biotechnology and its application in veterinary ...
... very good chemical sensors, researchers at the University of ... sensors are better when the graphene is "worse"more imperfections ... what you would want for transistors, for example," explained ... engineering and a member of the interdisciplinary research team. ...
... /PRNewswire-iReach/ --  Quantum Leap Innovations announced today ... of Directors.  Michael Cusumano is the Sloan Management Review ... Technology,s Sloan School of Management, with a joint appointment ... book, STAYING POWER , covers six enduring principles ...
Cached Biology Technology:Animal Biotechnology - Technologies, Markets and Companies 2Animal Biotechnology - Technologies, Markets and Companies 3Animal Biotechnology - Technologies, Markets and Companies 4Animal Biotechnology - Technologies, Markets and Companies 5Animal Biotechnology - Technologies, Markets and Companies 6Animal Biotechnology - Technologies, Markets and Companies 7Animal Biotechnology - Technologies, Markets and Companies 8Animal Biotechnology - Technologies, Markets and Companies 9Animal Biotechnology - Technologies, Markets and Companies 10Animal Biotechnology - Technologies, Markets and Companies 11Animal Biotechnology - Technologies, Markets and Companies 12Animal Biotechnology - Technologies, Markets and Companies 13Animal Biotechnology - Technologies, Markets and Companies 14Imperfections may improve graphene sensors 2Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 2Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 3Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 4
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... but is it attuned to the mind? A new study ... and modern dancers are not as emotionally in sync with ... UC Berkeley researchers tracked how closely the emotions of seasoned ... and heart rates. They found that dancers who devote ...
... York, NY, February 22, 2011 - The Vilcek Foundation is ... honoring the contributions of foreign-born scientists and artists. ... recognition of a sustained record of innovation and achievement, is ... Professor and head of the laboratory of Cell Biology and ...
... at Rice University has stepped forward with an efficient method ... properties -- and adds more. The new technique ... close contact with single-walled carbon nanotubes while keeping them separated ... manufacturers who want to spin fiber from nanotubes, or mix ...
Cached Biology News:Meditation beats dance for harmonizing body and mind 2Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 2Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 3Metallic molecules to nanotubes: Spread out! 2Metallic molecules to nanotubes: Spread out! 3
... is chromatographically purified from egg white. The extinction ... product is in 10 mM phosphate-buffered saline, ... albumin, 0.05% sodium azide and 50% glycerol. Avidin ... conjugate is purified by molecular sieving ...
in vitro Translation, Accessory Products...
Request Info...
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
Biology Products: